Steven Mah
Stock Analyst at TD Cowen
(1.97)
# 2,918
Out of 4,853 analysts
31
Total ratings
31.03%
Success rate
7.19%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $30.33 | +91.23% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $21.50 | +44.19% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $7.23 | +1,559.75% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $4.57 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $23.84 | +76.17% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $2.37 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.39 | +622.02% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.84 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.26 | +829.20% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $165.51 | -6.35% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.13 | +2,377.88% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $20.82 | +572.43% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.00 | +5,100.00% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $82.25 | +404.56% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $80 | $2.97 | +2,593.60% | 1 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $29.90 | +736.12% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $30.33
Upside: +91.23%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $21.50
Upside: +44.19%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $7.23
Upside: +1,559.75%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $4.57
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $23.84
Upside: +76.17%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.37
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.39
Upside: +622.02%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.84
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.26
Upside: +829.20%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $165.51
Upside: -6.35%
May 11, 2021
Initiates: Overweight
Price Target: $28
Current: $1.13
Upside: +2,377.88%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $20.82
Upside: +572.43%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.00
Upside: +5,100.00%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $82.25
Upside: +404.56%
Dec 16, 2020
Upgrades: Overweight
Price Target: $40 → $80
Current: $2.97
Upside: +2,593.60%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $29.90
Upside: +736.12%